Espinola Natalia, Rodríguez Cairoli Federico, Rojas-Roque Carlos, Luna Paula Carolina, Kanevsky Diego, Migliazza Valeria, Pichon-Riviere Andrés
Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Centre for Health Economics (CHE), Alcuin 'A' Block, University of York, York, UK.
Expert Rev Pharmacoecon Outcomes Res. 2025 Jan;25(1):101-111. doi: 10.1080/14737167.2024.2394124. Epub 2024 Aug 30.
Our study assessed the budget impact and cost per responder of upadacitinib15mg and 30 mg for moderate to severe atopic dermatitis (MS-AD) treatment from social security and private health sector perspective in Argentina.
A budget impact model was adapted to depict clinical and economic aspects of treatment over a 5-years horizon time. Scenario analyses and deterministic sensitivity analyses were performed. A 16-weeks cost per responder model was adapted based on a network meta-analysis. Primary analyses assessed the cost per Eczema Area and Severity Index 50, 75 and 90 at week 16.
The inclusion of upadacitinib 15 mg and 30 mg in the biological treatment mix for MS-AD was associated with an average budget saving per-member per-month ofU$S0.062 (social security) and U$S0.064 (private sector). Percentage of patients with access to treatment, acquisition cost of upadacitinib 30 mg and prevalence of MS-AD were the most influential parameters in the budget impact results. At week 16, upadacitinib 30 mg was associated with the lowest number needed to treat and the lowest cost per responder for all outcomes.
The introduction of upadacitinib in MS-AD treatment was associated with modest savings for the social security and private payer budget in Argentina.
我们的研究从阿根廷社会保障和私营医疗部门的角度，评估了15毫克和30毫克乌帕替尼治疗中度至重度特应性皮炎（MS-AD）的预算影响和每例缓解者的成本。
采用预算影响模型来描述5年时间范围内治疗的临床和经济方面。进行了情景分析和确定性敏感性分析。基于网络荟萃分析改编了一个16周每例缓解者成本模型。主要分析评估了第16周时湿疹面积和严重程度指数改善50%、75%和90%时的成本。
在MS-AD的生物治疗组合中纳入15毫克和30毫克乌帕替尼，平均每人每月可节省预算0.062美元（社会保障）和0.064美元（私营部门）。获得治疗的患者百分比、30毫克乌帕替尼的购置成本和MS-AD的患病率是预算影响结果中最具影响力的参数。在第16周时，30毫克乌帕替尼在所有结局中所需治疗人数最少，每例缓解者成本最低。
在阿根廷，将乌帕替尼引入MS-AD治疗与社会保障和私营支付方预算的适度节省相关。
